Frontiers in Clinical Drug Research - Dementia: Volume 2

Among neurodegenerative diseases, those that lead to a state ofdementia are the aim of severalinvestigations. Dementia is a chronic disease the prevalence of whichis increasing worldwide. Thenumber of dementia patients in the world is approximately 50 million,and it is estimated that thenumber of patients will reach 131.5 million by 2050. This increase willbe accompanied by asignificant increase in medical expenditures and other expenses,especially for elderly patients.Therefore, the maintenance cost of dementia in the future is expectedto be quite high. For thisreason, several investigations aim, firstly, to describe the keymechanisms involved in the originof dementia and, secondly, to establish preventive and therapeuticstrategies in order tounderstand and mitigate this debilitating pathology.

This volume of Frontiers in Clinical Drug Research -Dementia explores the current comorbidities that cause cognitiveimpairment and the current management alternatives for clinical cases ofdementia. The reviews contributed in these volume will provide readers with acurrent perspective on the subject.

The topics covered in this volume include:

• Comorbidities inducing mild cognitive impairment
• An evaluation ofthe risk caused by some pathological conditions
• Tau-targeted therapy in Alzheimer's disease
• History and currentstate- Emerging nanotherapeutic strategies in Alzheimer's disease
• Implication of dehydroepiandrosterone on dementia related tooxidative stress
• Polyphenol compounds as potential therapeutic agents in Alzheimer’sdisease

The volume is a timely update on dementia treatment for clinicalphysicians, neurologists, gerontologists, pharmaceutical and medicinal chemistryresearchers, and physiologists.